Colme (chloramphenicol)

Quick links

Choose a section

Quick links to important sections

Advertisements

Colme (chloramphenicol)

Advertisements
Advertisements

Overview of Colme (chloramphenicol)

Quick Facts

Property Description
Active Ingredient Chloramphenicol
Common Forms Oral capsules, Injectable solution, Eye/Ear drops, Eye ointment
Pharmacological Class Broad-spectrum antibiotic (Miscellaneous Antibiotics)
General Purpose Treatment of serious bacterial infections when alternatives are unsuitable
Origin Synthetic compound

What is Chloramphenicol (Colme) and its Pharmacological Class?

Chloramphenicol, the active ingredient in the product Colme, is categorized as a broad-spectrum antibiotic belonging to the pharmacological class of miscellaneous antibiotics. This antimicrobial agent is a synthetic compound, although it was historically derived from the soil bacterium Streptomyces venezuelae. Its broad-spectrum classification indicates effectiveness against a wide range of bacteria, including both Gram-positive and Gram-negative types. The medication functions through the inhibition of bacterial growth, a mechanism that assists the body in controlling the proliferation of harmful bacteria.


Composition, Forms, and General Therapeutic Purpose

Chloramphenicol is typically a single-ingredient product supplied in various pharmaceutical preparations to meet specific clinical requirements. The drug is available in oral capsules for systemic treatment, sterile injectable solution for intravenous administration, and localized forms such as eye drops, ear drops, and eye ointment. The general therapeutic purpose of this medication is the management of severe or life-threatening bacterial infections in cases where alternative treatments are considered unsuitable or ineffective. Its use is generally reserved for serious infections where resistance to other agents is present.


How Does Chloramphenicol Work to Fight Bacteria?

The primary physiological action of chloramphenicol is to combat infection by acting as a protein synthesis inhibitor within bacterial cells. The medicine works by preventing bacteria from growing and multiplying, an effect characterized as bacteriostatic. By stopping the formation of essential proteins, the drug limits the spread of the infection, allowing the body's natural immune defenses to eliminate the remaining pathogens. This mechanism involves the drug binding to the bacterial 50S ribosomal subunit.

Regulatory References

  1. EMA Guidance
  2. MedlinePlus
Advertisements

What side effects are possible with Colme (chloramphenicol)?

Possible Side Effects and Safety Information

The safety profile of chloramphenicol is officially defined by its potential for serious hematologic toxicity, which is why its use is reserved for severe infections where alternatives are deemed unsuitable. Regulatory documents distinguish between two types of adverse blood reactions: dose-related reversible bone marrow depression, which is common and typically resolves upon stopping the medication, and a rare, irreversible aplastic anemia, which is not dose-dependent and can have a delayed onset, occurring weeks or months after treatment cessation.


Official Adverse Reaction Groupings

Category Documented Effects
Blood and Lymphatic System Bone marrow depression (reversible/irreversible), aplastic anemia, hypoplastic anemia, thrombocytopenia.
Nervous System Peripheral neuritis, optic neuritis (associated with prolonged use).
Gastrointestinal Nausea, vomiting, diarrhea, stomatitis, glossitis.

Serious Safety Considerations

The most serious reactions explicitly documented in official labeling include Irreversible Aplastic Anemia and Gray Baby Syndrome. Gray Baby Syndrome is a life-threatening toxicity characterized by circulatory collapse and is a particular risk for neonates and infants due to their reduced capacity to clear the drug. This population-specific constraint is a critical element of the safety profile.

Regulatory Constraints

Chloramphenicol is officially contraindicated in patients with a history of hypersensitivity or pre-existing bone marrow depression. The risk of neurological effects, such as optic neuritis, is associated with prolonged use, which guides the overall safety monitoring requirements defined in prescribing information.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Chloramphenicol overdose describes serious, life-threatening manifestations requiring immediate emergency intervention. Documented overdose presentations may initially include nausea, vomiting, and abdominal distension.


Severe Outcomes and Help-Seeking Requirements

Overdose progression is officially documented to affect major physiological systems, leading to cardiovascular collapse, severe hypotension, and central nervous system effects such as seizure and coma. Immediate medical attention is required if an individual is unresponsive, has experienced a seizure, or is exhibiting trouble breathing or irregular respiration.


Population-Specific Overdose Considerations

A critical, officially documented risk is Gray Baby Syndrome, a severe and sometimes fatal outcome primarily affecting premature and newborn infants and children up to age two. Increased toxicity risk is also noted for patients with impaired hepatic function or impaired renal function. Authorities state that emergency medical treatment must be initiated, and management is generally supportive. Regulatory documentation emphasizes that there is no specific antidote for Chloramphenicol overdose. If overdose is suspected, authorities advise calling emergency services immediately.

Advertisements

Therapeutic Uses of Colme (chloramphenicol)

What Colme (Chloramphenicol) Treats: Main Uses and Benefits

Chloramphenicol (Colme) is an antibiotic generally reserved for addressing severe and life-threatening bacterial infections when common alternatives are ineffective or unsuitable. Its therapeutic use focuses strictly on managing serious conditions that present with intense, disruptive symptoms.

The medication is utilized for severe infections, such as rickettsial diseases, meningitis caused by specific bacteria, or typhoid fever, when less dangerous antimicrobials are ineffective or not tolerated. It is applicable within clinical settings that involve acute or unstable symptom patterns.

Therapeutic Focus Areas

The primary therapeutic benefit is associated with symptomatic relief across key domains, which assists with managing symptoms related to systemic imbalance and heightened physiological activity. This medication is commonly used across conditions presenting with acute episodes like systemic fevers, serious neuro-infections, and severe localized eye infections.

The medication may assist with addressing symptom clusters that may become intense or disruptive, such as profound high fever, severe chills, and neurological symptoms like headache and neck stiffness. This supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Severe Systemic Symptoms

Chloramphenicol is commonly used to help with symptoms related to systemic imbalance in critically ill patients, assisting with the management of pronounced fever and toxicity.

Regulatory References

  1. NIH StatPearls - Chloramphenicol
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Colme (Chloramphenicol)?

Eligibility for Colme (chloramphenicol) is strictly defined by regulatory authorities and centers on absolute contraindications and conditional use requirements.

The medicine is contraindicated and must not be used by individuals with a known history of hypersensitivity to chloramphenicol or any pre-existing blood dyscrasias (e.g., aplastic anaemia). Use is also prohibited when a patient is receiving concurrent medications that are liable to suppress bone marrow function. Furthermore, regulatory labeling explicitly contraindicates the use of the medicine for trivial infections, colds, influenza, or as a prophylactic agent.

Use is restricted and conditional for several populations. Systemic use in neonates and infants requires extreme caution, with mandatory dose adjustments and blood concentration monitoring due to the risk of “Gray Syndrome” toxicity. Patients with impaired hepatic or renal function are restricted and require specialized dose adjustment to manage toxicity risk. For pregnant women and those who are breastfeeding, the drug is not recommended; administration is only permitted if the potential benefit decisively justifies the documented risk to the fetus or infant.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Colme (chloramphenicol) is defined by its ability to inhibit metabolic enzymes and its additive physiological effects, strictly based on government regulatory documentation.

Metabolic (Pharmacokinetic) Interactions

Chloramphenicol is documented as an inhibitor of specific liver enzymes, primarily Cytochrome P450 (CYP) enzymes (including CYP2C9, CYP2C19, and CYP3A4). This pharmacokinetic interaction leads to reduced clearance and a subsequent increase in plasma levels (exposure) of co-administered medicines that are metabolized by these systems.

Interacting Substance/Class Official Interaction Outcome
Phenytoin, Dicumarol (Warfarin) Increased plasma levels and effects due to metabolic inhibition.
Chlorpropamide, Tolbutamide Increased effects due to reduced metabolic clearance.

Pharmacodynamic and Restriction Notes

A critical pharmacodynamic restriction is the mandated avoidance of combination with other drugs liable to cause bone marrow depression (e.g., methotrexate), due to the risk of additive myelosuppression. This restriction is formally stated in the drug’s regulatory documents.

  • Co-administration with live bacterial vaccines (such as cholera or typhoid) is restricted as the antibiotic may diminish the vaccine's efficacy.
  • Hepatic impairment is noted as a condition that slows drug clearance, heightening the risk of severe interactions in this population.
  • The drug can also decrease the response to iron and Vitamin B12 supplements.
Advertisements

Mechanism of Action

Targeted Blockade of the Bacterial 70S Ribosome

Chloramphenicol initiates its action by reversibly binding to the 50S ribosomal subunit of the bacterial 70S ribosome. This molecular targeting establishes a differential affinity for microbial 70S ribosomes. The drug's mechanism is concentrated on the bacteria, establishing the foundation for its action.

Functional Inhibition of Peptidyl Transferase

The binding to the 50S subunit directly inhibits the function of the peptidyl transferase enzyme within the peptidyl transferase center (PTC). This enzyme inhibition prevents the formation of the peptide bond necessary to link amino acids together. This action stops the elongation of bacterial protein chains, which ceases the protein synthesis necessary for growth.

Cascade to Bacteriostasis and Microbial Growth Arrest

The cessation of protein synthesis makes the cell unable to generate the essential structural and functional components needed for multiplication. This mechanistic cascade results in the physiological state of bacteriostasis (inhibition of microbial growth). This action arrests bacterial multiplication, reducing the ability of the organisms to increase in population size.

Mechanistic Limitations: Resistance and Selectivity Constraints

The efficacy of this mechanism is constrained by the bacterial enzyme Chloramphenicol Acetyltransferase (CAT), which inactivates the drug, thus preventing ribosomal binding. Furthermore, the drug possesses a low-level, non-selective affinity for mammalian mitochondrial ribosomes, resulting in a secondary effect on host cellular processes.

Advertisements

Dosage and Administration Information

Chloramphenicol is administered via distinct routes depending on the infection type. Systemic, serious infections are addressed using the Intravenous (IV) route or Oral formulations. Localized eye or ear infections are managed with Topical preparations, such as ophthalmic drops or ointment. The IV formulation is strictly for intravenous administration, as it is ineffective if given intramuscularly.


Official Dosing and Administration Principles

Standard Dosing and Frequency

Systemic dosing for adults and children is typically set at 50 mg/kg/day, which must be administered in divided doses every six hours to maintain consistent levels. For the most severe infections, the dose may temporarily be increased up to 100 mg/kg/day, followed by a reduction to the standard regimen as soon as possible.

Special Conditions and Duration

Oral capsules or suspension are generally taken on an empty stomach (one to two hours away from meals) with a full glass of water. The IV powder requires reconstitution with an aqueous diluent before administration. A significantly lower total daily dose of 25 mg/kg/day is required for neonates and young infants due to their immature metabolic processes, and dose adjustment is also mandatory for patients with known hepatic or renal impairment.

Treatment must be maintained for the full prescribed duration; for specific systemic conditions like typhoid fever, this extends to 8 to 10 days after the patient becomes afebrile. Topical use must be continued for at least 48 hours after the affected area appears normal.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Colme (Chloramphenicol)

The research available for the compound chloramphenicol, the active ingredient in Colme, is drawn from historical clinical trials and systematic reviews. This evidence base is documented in official sources describing the clinical evaluation of the compound for specific indications.


Evidence for Systemic Use in Severe Infections

This section summarizes the structure of research—including historical clinical trials, systematic reviews, and comparative studies—that has examined the systemic use of the compound for serious conditions, such as typhoid fever and bacterial meningitis, reflecting its role as a reserved agent in the evidence landscape.

For typhoid fever, research was studied for its application in conditions associated with acute or disruptive episodes. Comparative studies against modern alternatives documented findings related to clinical failure rates. Findings were mixed across studies, and a significant portion of this evidence originated from studies conducted before modern, standardized trial methodologies were developed. Comprehensive, large-scale randomized controlled trials (RCTs) against all current first-line agents are limited.

For bacterial meningitis, studies explored the overall rate of patient survival (mortality) and the assessment of neurological outcomes. Systematic reviews described patterns in the mortality rates observed when comparing chloramphenicol to alternative agents. However, the evidence is limited by the modest sample sizes and heterogeneity (differences) across the older trials.

Evidence for Localized Use in Eye and Ear Infections

This section describes the evidence base for the topical forms of the compound, focusing on research designs like placebo-controlled and comparative trials.

For acute bacterial conjunctivitis, extensive research was conducted, including numerous placebo-controlled and comparative RCTs. Findings described that differences in the time required for symptoms to clear were often reported as small across all tested groups. It remains challenging to isolate the specific pattern of change contributed by the compound, given the high rate of the condition's natural resolution documented in trials.

Research Gaps and What Remains Uncertain

The evidence quality varies across studies, largely because the key systemic indications rely on historical data that predate modern clinical trial standards. Comparative evidence is lacking against all current standard-of-care treatments in many settings. Additionally, the limited information for long-term outcomes means that the full picture of effects beyond the acute treatment phase is not fully established.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Colme (chloramphenicol) (FAQ)

Q: Is Colme (chloramphenicol) only for eye infections or can it be used for other things?

A: Colme (chloramphenicol) is formally indicated for more than just localized infections. While it is commonly used for eye infections in topical forms, regulatory documents state that the medicine is reserved for serious, life-threatening systemic bacterial infections when other, less restrictive treatments are not appropriate.

Q: Why is chloramphenicol sometimes described as a 'last resort' antibiotic?

A: Official guidelines recommend reserving the use of chloramphenicol because of the documented risk of serious blood disorders, including rare, irreversible aplastic anemia. This means regulatory authorities direct its use only for severe infections where the benefits are considered to decisively outweigh the risk, or when resistance to other antibiotics is present.

Q: What happens if I stop using Colme (chloramphenicol) too soon?

A: Regulatory information emphasizes that treatment must be maintained for the full prescribed duration, even if symptoms begin to improve. Stopping treatment earlier than instructed has been described in official information as carrying the risk of the infection returning or contributing to the development of drug-resistant bacteria.

Q: Does Colme (chloramphenicol) interact with common pain relievers like ibuprofen?

A: Official labeling notes that chloramphenicol can inhibit certain liver enzymes, such as CYP450, which are responsible for clearing many medicines from the body. This interaction may increase the plasma levels and effects of other drugs, but specific over-the-counter pain relievers are not uniformly listed in the primary regulatory warnings.

Q: What are the most common things people feel while using chloramphenicol eye drops?

A: The most common effects observed with the use of the ophthalmic forms are localized and transient. These include feelings of burning, stinging, or mild irritation of the eye right after application, which usually passes quickly. Some people may also experience temporary blurring of vision.

Q: Are there any specific vitamins or supplements that should not be taken with chloramphenicol?

A: Regulatory documents state that chloramphenicol may decrease the body's response to both iron and Vitamin B12 supplements. Furthermore, regulatory warnings state that use with other medicines or supplements known to suppress bone marrow function is contraindicated.

Q: How long do most people typically use the eye drops for a basic infection?

A: For common bacterial conjunctivitis, official guidance describes a total treatment duration usually limited to five days. It is stated that use must always be continued for at least 48 hours after the infected area appears to be back to normal.

Q: Does Colme (chloramphenicol) lose its effectiveness over time if it's been opened?

A: Official stability requirements mandate that ophthalmic preparations must be discarded 4 weeks (28 days) after opening. This requirement is intended to support the medicine's stability and sterility, which helps maintain its effectiveness for the full duration of its labeled use.

Q: Can I use other eye drops or ointments at the same time as Colme?

A: Official warnings note that the simultaneous use of other topical eye products is a condition for which patients should seek advice. If other topical medicines are necessary, specific guidance on the timing and sequencing of applications may be needed to ensure the medication is properly absorbed.

Q: How fast does Colme (chloramphenicol) usually start working for an eye infection?

A: Regulatory advisory statements recommend seeking medical advice if the symptoms of an eye infection do not start to show improvement within 48 hours of starting the treatment. A lack of change by this time is an observation for which official guidance advises seeking advice.

Q: Can using Colme (chloramphenicol) cause vision changes?

A: Yes, official labeling describes that temporary blurring of vision may occur shortly after applying the eye drops. Rare reports of more serious issues, such as optic neuritis (nerve inflammation) and impaired central vision, have been associated with prolonged use of the drug.

Q: Is the eye drop version as strong as the oral version of chloramphenicol?

A: The eye drop is formulated to deliver the drug directly to the affected eye tissue to treat a localized infection. In contrast, the oral form is intended to be absorbed systemically (throughout the body) to treat severe internal infections.

Q: What's the difference between Colme eye drops and Colme eye ointment?

A: Eye drops are a liquid form that clears quickly from the eye and are often used multiple times daily. Eye ointment is a thicker preparation designed to remain in the eye for a longer period and is often applied once at night or used for more severe localized infections.

Q: Are there any long-term effects associated with repeated use of Colme (chloramphenicol) eye drops?

A: Regulatory warnings indicate that prolonged or intermittent topical use has been associated with a risk of rare, serious side effects, including optic neuritis and a condition affecting the bone marrow. For this reason, long-term or intermittent use of the drug is subject to official restrictions.

Q: Does the research support using chloramphenicol for all types of bacterial infections?

A: Although chloramphenicol is classified as a broad-spectrum antibiotic, its clinical use is specifically restricted by guidelines. It is primarily reserved for certain serious infections and localized infections, such as conjunctivitis, and is not generally used for all types of bacterial infections.

Q: Why is Colme (chloramphenicol) still used today if newer antibiotics exist?

A: Its documented use continues because the drug is effective against certain rare, serious infections or in cases where resistance has developed to newer, less toxic alternative agents, maintaining its role as a reserved treatment option.

Q: Can contact lens wearers use Colme (chloramphenicol)?

A: Official warnings explicitly state that all types of contact lenses, particularly soft contact lenses, should not be worn while treating an eye infection with chloramphenicol preparations. This restriction is noted due to the risk of damage to the lens and potential for worsening the infection.

Q: How can I tell if the antibiotic is actually starting to help my infection?

A: Official documentation indicates that improvement is generally noticeable when the symptoms begin to clear up or lessen. If the infection does not start to get better within 48 hours of beginning the treatment, official guidance notes that observation may be a reason to seek advice.

Q: Do you need a prescription to get Colme (chloramphenicol) everywhere?

A: The regulatory status varies by country. In some regions, the ophthalmic drops and ointment may be available for over-the-counter purchase for use in adults and children aged 2 years and over for conjunctivitis. Other forms and uses typically require a prescription.

Q: Are there any known issues with people over 65 using chloramphenicol?

A: Official documents note that chloramphenicol has been used successfully in the elderly at standard dosages. The official adverse effect profile and incidence do not appear to indicate a different pattern of risk when compared to younger adults.

Q: Does being exposed to sunlight change the effect of chloramphenicol?

A: Official documentation notes that eye infections can sometimes cause an increased sensitivity to sunlight, known as photophobia, and this symptom may occur while using the drops. This is a symptom for which official guidance advises seeking advice if it persists.

Q: Is it normal for my eye to look slightly redder when I first start using the drops?

A: The most common effects reported with the eye drops include transient irritation, stinging, or a burning sensation upon application. If the product causes a mild, local application site reaction, the eye may appear somewhat red or irritated.

Q: Does Colme (chloramphenicol) cause sensitivity to light?

A: Yes, sensitivity to light, or photophobia, is listed in official documentation as a symptom that may occur while using the eye drops. Official guidance notes this symptom and advises seeking advice if it is severe or does not resolve.

Q: What is the minimum age officially described for using the eye drops?

A: In some jurisdictions, the eye drops and ointment are available without a prescription for use in adults and children who are aged 2 years and over. For use in children under 2 years, the medicine requires a prescription.

Q: Is it possible for the infection to come back after using Colme (chloramphenicol)?

A: If the medicine is discontinued too soon—that is, before the full prescribed duration is completed—the symptoms of the infection may return. This is why official guidelines stress that treatment must be maintained for the full course instructed.

Q: Can Colme (chloramphenicol) be used for skin infections?

A: The official indications listed in regulatory documentation are for systemic infections (administered intravenously or orally) and localized infections of the eye or ear (administered topically). Use for general skin infections is not a stated indication on official labels.

Q: What is the main reason Colme (chloramphenicol) is not used as widely as other antibiotics?

A: The primary reason for its restricted use is the drug’s potential for serious and rare hematologic toxicity, including a type of irreversible aplastic anemia. This significant safety risk limits its use to severe conditions where alternatives are not considered suitable.

Q: Can Colme (chloramphenicol) interact with birth control pills?

A: Official information suggests chloramphenicol may potentially interact with certain hormonal medications. Official information notes this potential interaction and advises seeking advice about its relevance.

Advertisements

How should Colme (chloramphenicol) be stored and disposed of?

Storage and Disposal Requirements

Chloramphenicol requires specific conditions to maintain stability, as mandated by regulatory documents.


Storage Conditions

Condition Requirement
Temperature Unopened eye drops must be stored in a refrigerator (2°C to 8°C); do not freeze. Eye ointment is stored below 25°C.
Protection The product must be protected from light and stored in a tightly closed container away from moisture.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

The medicine must be discarded 4 weeks (28 days) after opening for both eye drops and ointment. Do not use the medicine after the expiration date.

Disposal must follow regulatory guidance: unused or expired product must not be thrown away via wastewater or household waste. Consult a pharmacist for proper disposal through a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colme (chloramphenicol) found in:

A-Z Index: